Neurim Pharmaceuticals Ltd.
Privately held: no public share price · Israel
Assets
(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
0Diseases
| Target & Modality | |||
|---|---|---|---|
Melatonin prolonged-release(Circadin) | Phase 3 | Melatonin receptor (MT1/MT2) | Indication not yet linked |
Discontinued programmes (1)
Development of these assets stopped. Each page states the sourced discontinuation and keeps the trials as evidence history.
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Financial reports
No financial reports recorded.